Inclisiran added to Lincolnshire Formulary
Inclisiran is an injectable drug which is used for patients with hyperlipidaemia. Lincolnshire PACEF has classed Inclisiran as “Green” on the Lincolnshire Joint Formulary. This means it can be initiated by general practice clinicians.
Inclisiran is recommended as an option for patients with a history of a cardiovascular event PLUS low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, defined as:
- maximum tolerated statins with or without other lipid-lowering therapies or
- other lipid-lowering therapies when statins are not tolerated or are contraindicated.
General practice clinicians can initiate Inclisiran if they are confident to do so and can also seek Advice and Guidance from cardiology if they are not. A Lipidology A&G service is starting at ULHT in January 2022.
Inclisiran is administered as a subcutaneous injection into the abdomen, upper arm, or thigh. The recommended dose is 284 mg Inclisiran initially, at 3 months, then every 6 months. A recall process will need to be set up to ensure that patients receive their 3-month dose and subsequent six monthly doses.
When administered Inclisiran can be claimed as a Personally Administered Item via the monthly FP34D submission. This will fund the practice the cost of the drug and approximately £10 for recall and administration.